Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

The Future of Life Sciences: Innovative Trends Shaping the Industry

Jul 04, 2026By Sreejith Kanhirangadan

SK

Introduction to the Future of Life Sciences

The life sciences industry is at the forefront of innovation, constantly evolving to meet the challenges of modern healthcare and scientific research. As we look to the future, several key trends are emerging that promise to transform the industry. From cutting-edge technologies to novel research methodologies, the future of life sciences is both exciting and promising.

In this blog post, we will explore some of the most innovative trends shaping the industry today. These advancements are not only enhancing our understanding of biological systems but also improving patient care and outcomes.

future lab

Digital Transformation in Life Sciences

Embracing Big Data and AI

Digital transformation is a driving force in the life sciences, with big data and artificial intelligence (AI) leading the charge. The ability to analyze vast amounts of data quickly and accurately is revolutionizing everything from drug discovery to personalized medicine.

AI algorithms are being used to identify potential drug candidates, predict patient responses, and even assist in clinical trials. These technologies are enabling companies to bring new treatments to market faster and with greater precision.

Telemedicine and Remote Monitoring

The rise of telemedicine and remote monitoring technologies is another significant trend. These innovations are making healthcare more accessible and efficient, allowing patients to receive care without leaving their homes. Wearable devices and mobile health apps are also contributing to this shift, providing real-time health data to both patients and healthcare providers.

digital health

Advancements in Biotechnology

CRISPR and Gene Editing

Biotechnology is experiencing a revolution with the advent of CRISPR and other gene-editing technologies. These tools are enabling scientists to precisely alter genetic material, opening up new possibilities for treating genetic disorders, cancer, and other diseases.

CRISPR is not only transforming research but also offering potential cures that were once thought impossible. The ethical considerations and regulatory challenges associated with gene editing are still being navigated, but the potential benefits are immense.

Biomanufacturing and Synthetic Biology

Biomanufacturing and synthetic biology are also making waves in the life sciences sector. These fields are focused on using biological systems to produce materials, chemicals, and even medicines. By harnessing the power of nature, researchers are creating sustainable and efficient production methods that could redefine various industries.

biotechnology lab

Collaboration and Open Innovation

Collaboration and open innovation are becoming essential components of success in the life sciences. Companies, research institutions, and governments are increasingly working together to tackle complex challenges. By sharing knowledge and resources, these collaborations are accelerating the pace of discovery and application.

Open innovation platforms are allowing for greater transparency and collaboration, leading to breakthroughs that might not have been possible within isolated silos. The global response to the COVID-19 pandemic highlighted the importance of such collaborative efforts, setting a precedent for future initiatives.

Conclusion

The future of life sciences is bright, driven by technological advancements, innovative research, and collaborative efforts. As these trends continue to evolve, they will shape the industry in ways that enhance human health and well-being. By staying informed and adaptable, stakeholders in the life sciences can continue to lead the charge toward a healthier future.